Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Cash from Operations (2016 - 2025)

Dexcom (DXCM) has disclosed Cash from Operations for 16 consecutive years, with 294000000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations fell 2.46% to 294000000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 1440700000.0, a 45.6% increase, with the full-year FY2025 number at 1440700000.0, up 45.6% from a year prior.
  • Cash from Operations was 294000000.0 for Q4 2025 at Dexcom, down from 659900000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 659900000.0 in Q3 2025 to a low of 27800000.0 in Q1 2021.
  • A 5-year average of 214535000.0 and a median of 194900000.0 in 2023 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 1363.16% in 2021; the steepest drop was 60.03% in 2021.
  • Dexcom's Cash from Operations stood at 105800000.0 in 2021, then rose by 25.24% to 132500000.0 in 2022, then increased by 0.83% to 133600000.0 in 2023, then soared by 125.6% to 301400000.0 in 2024, then fell by 2.46% to 294000000.0 in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Cash from Operations are 294000000.0 (Q4 2025), 659900000.0 (Q3 2025), and 303000000.0 (Q2 2025).